Inclusion Criteria:

- Histologically confirmed transitional cell carcinoma or mixed histologies containing
a component of transitional cell carcinoma of the urothelium (renal pelvis, ureter,
bladder, urethra) with manifestations of progressing regional or metastatic cancer;
or (2) Nontransitional cell histologies include patients with adenocarcinoma or
squamous cell carcinomas representing greater than 90% of specimen; patients with
small cell carcinoma, soft tissue sarcomas, or carcinosarcomas are excluded

- Measurable disease, as defined in the RECIST criteria; all sites of disease must be
evaluated within 4 weeks prior to registration

- Patients must have progressed on one and only one prior systemic chemotherapy for
metastatic disease; prior chemotherapy administered in the adjuvant or neoadjuvant
setting is permitted (i.e. does not count as 1 prior regimen) provided that it was
completed greater than 12 months prior to the start of the first chemotherapy regimen
administered in the metastatic setting

- Patients must not have had prior systemic biologic response modifier therapy;
patients must not have had chemotherapy, hormonal or biologic therapy within 4 weeks
(6 weeks for nitrosoureas or mitomycin C) prior to entering the study or have
recovered from adverse events due to agents administered more than 4 weeks earlier

- Prior radiotherapy is allowed; patients must be >= 2 weeks post-radiotherapy at time
of registration; a previously irradiated lesion can only be used as a marker lesion
if there is unequivocal evidence of progression demonstrated on serial imaging
studies; patients must have recovered from all toxicities associated with prior
radiotherapy

- Patients must be >= 4 weeks post-major surgery at time of registration; patients must
have recovered from all toxicities associated with prior surgery

- ECOG performance status of 0 or 1

- No history of severe cardiovascular disease (AHA Class III or IV), uncontrolled CHF,
uncontrolled hypertension, or ventricular dysrhythmias

- Patients with previously resected and irradiated CNS metastases with evidence of
stable disease are eligible

- Patients with a history of prior malignancy are eligible provided they were treated
with curative intent and have been disease free for >= 5 years; curatively treated
basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix
must have been treated with curative intent; patients with clinically unsuspected
organ confined prostate cancer found at the time of cystoprostatectomy are eligible

- Creatinine < 1.5 mg/dL

- Granulocytes >= 1500/mm^3

- Platelets >= 100,000/mm^3

- AST =< 2.5 x institutional upper limit of normal

- Bilirubin < 1.5 mg/dl

- No active unresolved infection requiring parenteral antibiotics < 7 days prior to
study entry

- Patients must not have a swallowing dysfunction which would prevent the ingesting of
pills

- Patients must not have any evidence of bleeding diathesis

- Patients must not be on therapeutic anticoagulation; prophylactic anticoagulation
(i.e. low dose warfarin) of venous or arterial access devices is allowed provided
that the requirements for PT, INR or PTT are met

- Patients must not be taking the cytochrome P450 enzyme-inducing antiepileptic drugs
(phenytoin, carbamazepine, and phenobarbital), rifampin, or St. John's Wort

- Women of childbearing potential must not be pregnant (as proven by a negative
pregnancy test within 14 days prior to registration) or breast feeding because the
effects of this treatment on the fetus and breast-fed infants is unknown

- Women of childbearing potential and sexually active males must be strongly advised to
use an accepted and effective method of contraception